English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited disease among primary diseases in dialysis patients. Tolvaptan is known to improve increases in total kidney volume (TKV) in patients with ADPKD, thereby slowing the progression of kidney dysfunction. However, TKV is not always measured using magnetic resonance imaging (MRI), and the specific effect of tolvaptan has yet to be determined.

renal replacement therapy

Magnetic resonance imaging is effective for evaluating the therapeutic effect of tolvaptan on total kidney volume in patients with autosomal dominant polycystic kidney disease